PMID- 20382498
OWN - NLM
STAT- MEDLINE
DCOM- 20110214
LR  - 20171116
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 64
IP  - 7
DP  - 2010 Sep
TI  - Vaccination with immature dendritic cells combined with CD40mAb induces 
      protective immunity against B lymphoma in hu-SCID mice.
PG  - 487-92
LID - 10.1016/j.biopha.2010.01.004 [doi]
AB  - Dendritic cells (DCs) pulsed by tumor antigens have been widely used as tumor 
      vaccines to specifically trigger the cytotoxicity of CD8+ T cells. But the tumor 
      microenviroment with enriched immunosuppressants hampered DC maturation and 
      co-stimulation. CD40/CD40L signaling, one of the most important co-stimulatory 
      molecules is capable of effectively skewing the immune response by promoting DCs 
      maturation and co-stimulation. To establish a novel specific immunotherapeutic 
      approach for the use of DC vaccine in the treatment of B lymphoma, hu-SCID mice 
      bearing B lymphoma were vaccinated by different combination of tumor antigen 
      pulsed DC or imDC vaccines and immune-enhancing agencies such as agonist CD40mAb 
      and T cells. The results of immature DCs combined with agonistic CD40mAb were 
      encouraging with achievement of tumor regression and induction of 
      antigen-specific immune responses. These findings demonstrated the potential 
      utility of imDC-based tumor vaccination combining with agonistic CD40mAb in the 
      treatment of malignant lymphoma.
CI  - 2010 Elsevier Masson SAS. All rights reserved.
FAU - Ge, Yan
AU  - Ge Y
AD  - Biotechnology Research Institute, Soochow University, 708, Renmin Road, Suzhou, 
      215007 Jiangsu, China.
FAU - Xi, Hong
AU  - Xi H
FAU - Zhang, Xue-Guang
AU  - Zhang XG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100304
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CD40 Antigens)
RN  - 0 (Cancer Vaccines)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/*therapeutic use
MH  - Antigens, Neoplasm/immunology
MH  - B-Lymphocytes/immunology
MH  - CD40 Antigens/*immunology
MH  - CD40 Ligand/*immunology
MH  - Cancer Vaccines/*immunology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunity
MH  - Interferon-gamma/blood
MH  - Lymphocyte Culture Test, Mixed
MH  - Lymphoma, B-Cell/*immunology/*therapy
MH  - Mice
MH  - Mice, SCID
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Treatment Outcome
MH  - Vaccination
EDAT- 2010/04/13 06:00
MHDA- 2011/02/15 06:00
CRDT- 2010/04/13 06:00
PHST- 2009/10/24 00:00 [received]
PHST- 2010/01/25 00:00 [accepted]
PHST- 2010/04/13 06:00 [entrez]
PHST- 2010/04/13 06:00 [pubmed]
PHST- 2011/02/15 06:00 [medline]
AID - S0753-3322(10)00030-2 [pii]
AID - 10.1016/j.biopha.2010.01.004 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2010 Sep;64(7):487-92. doi: 10.1016/j.biopha.2010.01.004. 
      Epub 2010 Mar 4.